pubmed-article:2295065 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:2295065 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
pubmed-article:2295065 | lifeskim:mentions | umls-concept:C1366557 | lld:lifeskim |
pubmed-article:2295065 | lifeskim:mentions | umls-concept:C1704256 | lld:lifeskim |
pubmed-article:2295065 | lifeskim:mentions | umls-concept:C0699790 | lld:lifeskim |
pubmed-article:2295065 | lifeskim:mentions | umls-concept:C0007589 | lld:lifeskim |
pubmed-article:2295065 | lifeskim:mentions | umls-concept:C0062641 | lld:lifeskim |
pubmed-article:2295065 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
pubmed-article:2295065 | lifeskim:mentions | umls-concept:C1511938 | lld:lifeskim |
pubmed-article:2295065 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:2295065 | pubmed:dateCreated | 1990-2-13 | lld:pubmed |
pubmed-article:2295065 | pubmed:abstractText | The differentiation agent hexamethylene bisacetamide (HMBA) increased expression of transforming growth factor beta 1 (TGF beta 1) mRNA in HT29 colon carcinoma cells. The increase was evident after 24 h and was maintained at levels 4-5-fold the control levels for at least 5-13 days. No increase in expression of TGF beta 2 or TGF alpha mRNA was observed. Both TGF beta 1 and HMBA induced loss of expression of a cell surface malignancy marker on HT29 cells, and both decreased cell growth in serum-free medium. Exogenously applied TGF beta 1 mimicked the growth-arresting effect of HMBA on three surgically resected moderately differentiated colon carcinomas in serum-free primary culture. Both TGF beta 1 and HMBA increased the tumor growth fraction in a second group of three more aggressive colon carcinomas, while neither agent had any measurable growth-modulating activity on two other colon carcinomas. The induction of TGF beta 1 mRNA by HMBA along with the parallel biological effects of HMBA and exogenously applied TGF beta 1 on resected carcinomas and on HT29 cells suggest that the effects of HMBA on colon carcinoma cells may be mediated in part by induction of TGF beta 1. | lld:pubmed |
pubmed-article:2295065 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2295065 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2295065 | pubmed:language | eng | lld:pubmed |
pubmed-article:2295065 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2295065 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:2295065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2295065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2295065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2295065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2295065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2295065 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:2295065 | pubmed:month | Jan | lld:pubmed |
pubmed-article:2295065 | pubmed:issn | 0008-5472 | lld:pubmed |
pubmed-article:2295065 | pubmed:author | pubmed-author:RifkinJJ | lld:pubmed |
pubmed-article:2295065 | pubmed:author | pubmed-author:FriedmanEE | lld:pubmed |
pubmed-article:2295065 | pubmed:author | pubmed-author:CoffeyR JRJ | lld:pubmed |
pubmed-article:2295065 | pubmed:author | pubmed-author:WinawerSS | lld:pubmed |
pubmed-article:2295065 | pubmed:author | pubmed-author:SchroyPP | lld:pubmed |
pubmed-article:2295065 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:2295065 | pubmed:day | 15 | lld:pubmed |
pubmed-article:2295065 | pubmed:volume | 50 | lld:pubmed |
pubmed-article:2295065 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:2295065 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:2295065 | pubmed:pagination | 261-5 | lld:pubmed |
pubmed-article:2295065 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
pubmed-article:2295065 | pubmed:meshHeading | pubmed-meshheading:2295065-... | lld:pubmed |
pubmed-article:2295065 | pubmed:meshHeading | pubmed-meshheading:2295065-... | lld:pubmed |
pubmed-article:2295065 | pubmed:meshHeading | pubmed-meshheading:2295065-... | lld:pubmed |
pubmed-article:2295065 | pubmed:meshHeading | pubmed-meshheading:2295065-... | lld:pubmed |
pubmed-article:2295065 | pubmed:meshHeading | pubmed-meshheading:2295065-... | lld:pubmed |
pubmed-article:2295065 | pubmed:meshHeading | pubmed-meshheading:2295065-... | lld:pubmed |
pubmed-article:2295065 | pubmed:meshHeading | pubmed-meshheading:2295065-... | lld:pubmed |
pubmed-article:2295065 | pubmed:meshHeading | pubmed-meshheading:2295065-... | lld:pubmed |
pubmed-article:2295065 | pubmed:meshHeading | pubmed-meshheading:2295065-... | lld:pubmed |
pubmed-article:2295065 | pubmed:year | 1990 | lld:pubmed |
pubmed-article:2295065 | pubmed:articleTitle | Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide. | lld:pubmed |
pubmed-article:2295065 | pubmed:affiliation | Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021. | lld:pubmed |
pubmed-article:2295065 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:2295065 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:2295065 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295065 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295065 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295065 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295065 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295065 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295065 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2295065 | lld:pubmed |